Mylan’s EpiPen School Sales Trigger N.Y. Antitrust Probe
- Drugmaker has been criticized over increase in EpiPen price
- Probe will focus on Mylan’s contracts with New York schools
Mylan NV's EpiPen allergy shots sit on display for a photograph in Princeton, Illinois, U.S., on Friday, Aug. 26, 2016. In response to intense criticism over the past few days, Mylan NV moved Thursday to expand assistance programs that help patients with high out-of-pocket expenses -- but didn't go as far as cutting the treatment's list price. Health insurers and U.S. lawmakers criticized the effort as an attempt to cover a 400 percent price hike that won't make the drug more affordable.
Photographer: Daniel Acker/BloombergNew York state’s top cop opened an antitrust investigation into Mylan NV, saying the embattled drugmaker may have ripped off local school systems that purchased life-saving EpiPen shots for students.
New York Attorney General Eric Schneiderman said on Tuesday that a preliminary probe showed Mylan may have added anticompetitive terms to sales contracts with the schools. It’s the latest fallout for the company after a 500 percent price hike triggered outrage by lawmakers and the public.